Danone’s Specialized Nutrition division, led by its Oikos Greek yogurt brand, has seen double-digit volume growth in high-protein products over the past year. Management attributes this acceleration to rising adoption of GLP-1 weight-loss medications, which CoBank and Cornell University studies link to increased consumer spending on protein-rich foods. With U.S. consumers’ demand for dietary protein rising from 59% in 2022 to 70% in 2025, Danone has expanded production capacity by 15% at its primary yogurt plants in France and the U.S. to capture premium margins. High-protein dairy products command up to a 12% price premium over standard offerings, positioning Danone to boost both top-line revenue and segment profitability in 2026.

In response to updated guidance from European and U.S. food safety authorities, Danone announced a voluntary recall of a limited number of infant formula batches produced at its Ireland facility. The company emphasized that routine controls and additional analyses confirm its products meet all safety regulations. Danone said the recall affects less than 0.5% of its Specialized Nutrition segment volume and will have a minimal impact on full-year sales, given existing inventory buffers and rerouting of unaffected production. Danone has established dedicated carelines in key markets and expects to complete withdrawals by the end of Q1. Investors are monitoring potential reputational effects but note Danone’s €27.4 billion in 2024 sales and B Corp certification underpin long-term brand resilience.